Revenue rises sharply, but losses deepen and cash burn increases

Revenue Growth 20pctPat NegativeEbitda Margin CompressionResults RestatedRelated Party TransactionsNegative Operating CashflowResults View source PDF Explain this filing

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹1270.00

prior close

₹1260.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+4.1% vs market

Pharmaceuticals peers, median of 171sector+0.4%+4.4% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+2.7

15m

+3.8

30m

+3.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+0.7+4.1+0.4+4.4

Next day

+4.3pendingpending-0.7+4.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zota approved unaudited second-quarter and first-half results for September 2026. Consolidated operating revenue rose 54.6% year on year to Rs 199.33 crore in the quarter and 60.4% to Rs 372.93 crore for the half year, but the half-year net loss widened to about Rs 69.19 crore. Standalone half-year profit fell about 80.9% to Rs 3.02 crore. Operating cash outflow was Rs 51.05 crore. The limited review was unmodified.

Likely market impact

Revenue growth helps, but the wider loss, lower standalone profit and cash burn are negative for shareholders and may weigh on the stock.